Literature DB >> 32065348

Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs.

Hui Luo1,2, Qiao-Ling Tang3, Ya-Xi Shang2,3, Shi-Bing Liang2,3, Ming Yang2,3, Nicola Robinson2,4, Jian-Ping Liu5,6.   

Abstract

OBJECTIVE: Since December 2019, an outbreak of corona virus disease 2019 (COVID-19) occurred in Wuhan, and rapidly spread to almost all parts of China. This was followed by prevention programs recommending Chinese medicine (CM) for the prevention. In order to provide evidence for CM recommendations, we reviewed ancient classics and human studies.
METHODS: Historical records on prevention and treatment of infections in CM classics, clinical evidence of CM on the prevention of severe acute respiratory syndrome (SARS) and H1N1 influenza, and CM prevention programs issued by health authorities in China since the COVID-19 outbreak were retrieved from different databases and websites till 12 February, 2020. Research evidence included data from clinical trials, cohort or other population studies using CM for preventing contagious respiratory virus diseases.
RESULTS: The use of CM to prevent epidemics of infectious diseases was traced back to ancient Chinese practice cited in Huangdi's Internal Classic (Huang Di Nei Jing) where preventive effects were recorded. There were 3 studies using CM for prevention of SARS and 4 studies for H1N1 influenza. None of the participants who took CM contracted SARS in the 3 studies. The infection rate of H1N1 influenza in the CM group was significantly lower than the non-CM group (relative risk 0.36, 95% confidence interval 0.24-0.52; n=4). For prevention of COVID-19, 23 provinces in China issued CM programs. The main principles of CM use were to tonify qi to protect from external pathogens, disperse wind and discharge heat, and resolve dampness. The most frequently used herbs included Radix astragali (Huangqi), Radix glycyrrhizae (Gancao), Radix saposhnikoviae (Fangfeng), Rhizoma Atractylodis Macrocephalae (Baizhu), Lonicerae Japonicae Flos (Jinyinhua), and Fructus forsythia (Lianqiao).
CONCLUSIONS: Based on historical records and human evidence of SARS and H1N1 influenza prevention, Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population. Prospective, rigorous population studies are warranted to confirm the potential preventive effect of CM.

Entities:  

Keywords:  Chinese medicine; clinical evidence; corona virus disease 2019 (COVID-19); prevention program; review

Mesh:

Substances:

Year:  2020        PMID: 32065348      PMCID: PMC7088641          DOI: 10.1007/s11655-020-3192-6

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs
  166 in total

Review 1.  Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic.

Authors:  Rabeea Siddique; Qian Bai; Muhammad Adnan Shereen; Ghulam Nabi; Guang Han; Farooq Rashid; Saeed Ahmed; Aigerim Benzhanova; Mengzhou Xue; Suliman Khan
Journal:  Hum Vaccin Immunother       Date:  2020-10-16       Impact factor: 3.452

Review 2.  Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.

Authors:  S F Yanuck; J Pizzorno; H Messier; K N Fitzgerald
Journal:  Integr Med (Encinitas)       Date:  2020

Review 3.  COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

Authors:  Dâmaris Silveira; Jose Maria Prieto-Garcia; Fabio Boylan; Omar Estrada; Yris Maria Fonseca-Bazzo; Claudia Masrouah Jamal; Pérola Oliveira Magalhães; Edson Oliveira Pereira; Michal Tomczyk; Michael Heinrich
Journal:  Front Pharmacol       Date:  2020-09-23       Impact factor: 5.810

Review 4.  Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.

Authors:  Yinan Xiao; Hanyue Xu; Wen Guo; Yunuo Zhao; Yuling Luo; Ming Wang; Zhiyao He; Zhenyu Ding; Jiyan Liu; Lei Deng; Fushen Sha; Xuelei Ma
Journal:  Mol Biomed       Date:  2020-12-03

5.  Properties of the Novel Chinese Herbal Medicine Formula Qu Du Qiang Fei I Hao Fang Warrant Further Research to Determine Its Clinical Efficacy in COVID-19 Treatment.

Authors:  Jennifer Cruz; Jason Trombley; Linda Carrington; Xiaodong Cheng
Journal:  Med Acupunct       Date:  2021-02-16

Review 6.  Therapeutic Potentials of Antiviral Plants Used in Traditional African Medicine With COVID-19 in Focus: A Nigerian Perspective.

Authors:  Alfred Francis Attah; Adeshola Adebayo Fagbemi; Olujide Olubiyi; Hannah Dada-Adegbola; Akinseinde Oluwadotun; Anthony Elujoba; Chinedum Peace Babalola
Journal:  Front Pharmacol       Date:  2021-04-26       Impact factor: 5.810

Review 7.  An update on emerging therapeutics to combat COVID-19.

Authors:  Naveed Nazir Shah; Showkat Ul Nabi; Muzafar Ahmad Rather; Qudratullah Kalwar; Sofi Imtiyaz Ali; Wajid Mohammad Sheikh; Alveena Ganai; Showkeen Muzamil Bashir
Journal:  Basic Clin Pharmacol Toxicol       Date:  2021-06-11       Impact factor: 3.688

Review 8.  Analysis of Available Nutrition Recommendations to Combat COVID-19: A Scoping Review.

Authors:  Norsyamlina Che Abdul Rahim; Jayvikramjit Singh Manjit Singh; Munawara Pardi; Ahmad Ali Zainuddin; Ruhaya Salleh
Journal:  Malays J Med Sci       Date:  2021-06-30

9.  Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2.

Authors:  Shafi Mahmud; Gobindo Kumar Paul; Suvro Biswas; Shamima Afrose; Mohasana Akter Mita; Md Robiul Hasan; Mst Sharmin Sultana Shimu; Alomgir Hossain; Maria Meha Promi; Fahmida Khan Ema; Kumarappan Chidambaram; Balakumar Chandrasekaran; Ali M Alqahtani; Talha Bin Emran; Md Abu Saleh
Journal:  Front Mol Biosci       Date:  2021-05-10

Review 10.  Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection.

Authors:  Seyed Abdulmajid Ayatollahi; Javad Sharifi-Rad; Patrick Valere Tsouh Fokou; Gail B Mahady; Hafiz Ansar Rasul Suleria; Shivani Krishna Kapuganti; Kundlik Gadhave; Rajanish Giri; Neha Garg; Rohit Sharma; Daniel Ribeiro; Célia F Rodrigues; Željko Reiner; Yasaman Taheri; Natália Cruz-Martins
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.